Drug Trial Radar · NCT02516241
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,126
Actual
Start
Nov 2, 2015
Primary completion
Jan 27, 2020
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 5, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
Conditions
- Urothelial Cancer
Interventions
MEDI4736 (Durvalumab)Drug
IV infusion
TremelimumabDrug
IV infusion
CisplatinDrug
IV infusion
CarboplatinDrug
IV infusion
GemcitabineDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis SetTime frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
- To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis SetTime frame: From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Locations
222 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Stanford, California
Research Site
Aurora, Colorado
Research Site
New Haven, Connecticut
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Louisville, Kentucky
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Detroit, Michigan
Research Site
Omaha, Nebraska
Research Site
New York, New York
Research Site
New York, New York
Research Site
Memphis, Tennessee
Research Site
Nashville, Tennessee
Research Site
Seattle, Washington
Research Site
Box Hill, Australia
Research Site
Elizabeth Vale, Australia
Research Site
Macquarie University, Australia
Research Site
St Leonards, Australia
Research Site
Waratah, Australia
Research Site
Linz, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Barretos, Brazil
Research Site
Belo Horizonte, Brazil
Research Site
Ijuí, Brazil
Research Site
Itajaí, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Showing 40 of 222 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.